Formulation and clinical perspectives of inhalation-based nanocarrier delivery: a new archetype in lung cancer treatment

Despite tremendous research in targeted delivery and specific molecular inhibitors (gene delivery), cytotoxic drug delivery through inhalation has been seen as a core part in the treatment of the lung cancer. Inhalation delivery provides a high dose of the drug directly to the lungs without affecting other body organs, increasing the therapeutic ratio. This article reviews the research performed over the last several decades regarding inhalation delivery of various cancer therapeutics for the treatment of lung cancer. Nevertheless, pulmonary administration of nanocarrier-based cancer therapeutics for lung cancer therapy is still in its infancy and faces greater than expected challenges. This article focuses on the current inhalable nanocarrier-based drugs for lung cancer treatment.

Download Full-text

Imaging Biomarkers of Tumour Proliferation and Invasion for Personalised Lung Cancer Therapy

Journal of Personalized Medicine ◽

10.3390/jpm10040222 ◽

2020 ◽

Vol 10 (4) ◽

pp. 222

Author(s):

Loredana G. Marcu

Keyword(s):

Lung Cancer ◽

Cancer Therapy ◽

Cancer Treatment ◽

Critical Role ◽

Imaging Biomarkers ◽

Lung Cancer Treatment ◽

Cancer Management ◽

Specificity And Sensitivity ◽

Lung Cancer Therapy ◽

Tumour Proliferation

Personalised treatment in oncology has seen great developments over the last decade, due to both technological advances and more in-depth knowledge of radiobiological processes occurring in tumours. Lung cancer therapy is no exception, as new molecular targets have been identified to further increase treatment specificity and sensitivity. Yet, tumour resistance to treatment is still one of the main reasons for treatment failure. This is due to a number of factors, among which tumour proliferation, the presence of cancer stem cells and the metastatic potential of the primary tumour are key features that require better controlling to further improve cancer management in general, and lung cancer treatment in particular. Imaging biomarkers play a key role in the identification of biological particularities within tumours and therefore are an important component of treatment personalisation in radiotherapy. Imaging techniques such as PET, SPECT, MRI that employ tumour-specific biomarkers already play a critical role in patient stratification towards individualized treatment. The aim of the current paper is to describe the radiobiological challenges of lung cancer treatment in relation to the latest imaging biomarkers that can aid in the identification of hostile cellular features for further treatment adaptation and tailoring to the individual patient’s needs.

Download Full-text

Chemo-biologic combinatorial drug delivery using folate receptor-targeted dendrimer nanoparticles for lung cancer treatment

Nanomedicine Nanotechnology Biology and Medicine ◽

10.1016/j.nano.2017.11.010 ◽

2018 ◽

Vol 14 (2) ◽

pp. 373-384 ◽

Cited By ~ 29

Author(s):

Narsireddy Amreddy ◽

Anish Babu ◽

Janani Panneerselvam ◽

Akhil Srivastava ◽

Ranganayaki Muralidharan ◽

...

Keyword(s):

Lung Cancer ◽

Drug Delivery ◽

Cancer Treatment ◽

Folate Receptor ◽

Lung Cancer Treatment

Download Full-text

Synthesis and surface modification of mesoporous metal-organic framework (UiO-66) for efficient pH-responsive drug delivery and lung cancer treatment

Nanotechnology ◽

10.1088/1361-6528/abf7ea ◽

2021 ◽

Author(s):

Canguo Xie ◽

Bitao Guo ◽

Hua You ◽

Zhengyan Wang ◽

Qiqi Leng ◽

...

Keyword(s):

Lung Cancer ◽

Drug Delivery ◽

Surface Modification ◽

Cancer Treatment ◽

Metal Organic Framework ◽

Ph Responsive ◽

Lung Cancer Treatment ◽

Metal Organic ◽

Mesoporous Metal ◽

Organic Framework

Download Full-text

Lung cancer: Treatment with high dose, split course irradiation using cobalt-60, 10 MeV and 32 MeV photons

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/0360-3016(78)90646-6 ◽

1978 ◽

Vol 4 ◽

pp. 57

Author(s):

M.H. Olson ◽

P. Ray ◽

K. Shah ◽

A.E. Wright

Keyword(s):

Lung Cancer ◽

Cancer Treatment ◽

High Dose ◽

Lung Cancer Treatment

Download Full-text

Signaling Pathway Inhibitors, miRNA, and Nanocarrier-Based Pharmacotherapeutics for the Treatment of Lung Cancer: A Review

Pharmaceutics ◽

10.3390/pharmaceutics13122120 ◽

2021 ◽

Vol 13 (12) ◽

pp. 2120

Author(s):

Shadab Md ◽

Nabil A. Alhakamy ◽

Shahid Karim ◽

Gamal A Gabr ◽

Mohammad Kashif Iqubal ◽

...

Keyword(s):

Lung Cancer ◽

Drug Delivery ◽

Adverse Effects ◽

Cancer Treatment ◽

New Drugs ◽

Lung Cancer Treatment ◽

Anticancer Effects ◽

Therapeutic Outcomes ◽

Promising Target ◽

Approved Drugs

Lung cancer is one of the most commonly diagnosed cancers and is responsible for a large number of deaths worldwide. The pathogenic mechanism of lung cancer is complex and multifactorial in origin. Thus, various signaling pathways as targets for therapy are being examined, and many new drugs are in the pipeline. However, both conventional and target-based drugs have been reported to present significant adverse effects, and both types of drugs can affect the clinical outcome in addition to patient quality of life. Recently, miRNA has been identified as a promising target for lung cancer treatment. Therefore, miRNA mimics, oncomiRs, or miRNA suppressors have been developed and studied for possible anticancer effects. However, these miRNAs also suffer from the limitations of low stability, biodegradation, thermal instability, and other issues. Thus, nanocarrier-based drug delivery for the chemotherapeutic drug delivery in addition to miRNA-based systems have been developed so that existing limitations can be resolved, and enhanced therapeutic outcomes can be achieved. Thus, this review discusses lung cancer’s molecular mechanism, currently approved drugs, and their adverse effects. We also discuss miRNA biosynthesis and pathogenetic role, highlight pre-clinical and clinical evidence for use of miRNA in cancer therapy, and discussed limitations of this therapy. Furthermore, nanocarrier-based drug delivery systems to deliver chemotherapeutic drugs and miRNAs are described in detail. In brief, the present review describes the mechanism and up-to-date possible therapeutic approaches for lung cancer treatment and emphasizes future prospects to bring these novel approaches from bench to bedside.

Download Full-text